LAGIE

Legend Capital leads ForQaly Medical's Series B financing

Retrieved on: 
Friday, October 8, 2021
Singular, NASDAQ, PCI, Cardiogenic shock, LAGIE, VAD, Evidence-based medicine, Capital, Eli Lilly and Company, Asia, Solution, Patient, Research, Venture, Pharmaceutical industry

Recently, it completed its Series B fundraising led by Legend Capital, followed by CD Capital, SAIF Partners, Chengwei Chuangban and Co-win Ventures.

Key Points: 
  • Recently, it completed its Series B fundraising led by Legend Capital, followed by CD Capital, SAIF Partners, Chengwei Chuangban and Co-win Ventures.
  • Existing investors Lilly Asia Ventures and Kaitai Capital also participated in the funding round.
  • Joe Zhou, the Managing Director of Legend Capital, said: "VAD, especially the interventional one, has a huge market prospect in China.
  • We are glad to partner with ForQaly Medical and will establish a long-term cooperation with the company.